ASCO 2026: RAS Is No Longer Undruggable
For decades, oncologists and drug developers shared an undeniable truth: KRAS – one of the most commonly mutated genes in human cancer – was untargetable. Mutations in KRAS drive approximately 25% of all cancers, including most pancreatic adenocarcinomas, roughly 40% of colorectal cancers, and about 30% of non-small cell lung cancers. For years, despite enormous efforts in clinical research and financial investments, every attempt to inhibit RAS directly had failed. The protein was labelled "undruggable," and the field largely accepted the verdict.